Cargando…
Development and validation of a Bayesian survival model for inclusion body myositis
BACKGROUND: Associations between disease characteristics and payer-relevant outcomes can be difficult to establish for rare and progressive chronic diseases with sparse available data. We developed an exploratory bridging model to predict premature mortality from disease characteristics, and using i...
Autores principales: | Capkun, Gorana, Schmidt, Jens, Ghosh, Shubhro, Sharma, Harsh, Obadia, Thomas, de Vera, Ana, Risson, Valery, Amzal, Billy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836518/ https://www.ncbi.nlm.nih.gov/pubmed/31694651 http://dx.doi.org/10.1186/s12976-019-0114-4 |
Ejemplares similares
-
Immune and myodegenerative pathomechanisms in inclusion body myositis
por: Keller, Christian W., et al.
Publicado: (2017) -
Survival and associated comorbidities in inclusion body
myositis
por: Naddaf, Elie, et al.
Publicado: (2021) -
Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010) -
Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis
por: Lindgren, Ulrika, et al.
Publicado: (2022) -
Correction to: Survival and associated comorbidities in inclusion body myositis
Publicado: (2022)